Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
DCTH's Cash to Debt is ranked higher than
98% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. DCTH: No Debt )
DCTH' s 10-Year Cash to Debt Range
Min: 1.97   Max: No Debt
Current: No Debt

Equity to Asset 0.77
DCTH's Equity to Asset is ranked higher than
83% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DCTH: 0.77 )
DCTH' s 10-Year Equity to Asset Range
Min: 0.61   Max: 0.84
Current: 0.77

0.61
0.84
F-Score: 5
Z-Score: -12.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1930.47
DCTH's Operating margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. DCTH: -1930.47 )
DCTH' s 10-Year Operating margin (%) Range
Min: -15569.65   Max: -4179.62
Current: -1930.47

-15569.65
-4179.62
Net-margin (%) -1722.85
DCTH's Net-margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. DCTH: -1722.85 )
DCTH' s 10-Year Net-margin (%) Range
Min: -14990.75   Max: -3838.48
Current: -1722.85

-14990.75
-3838.48
ROE (%) -72.01
DCTH's ROE (%) is ranked higher than
50% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. DCTH: -72.01 )
DCTH' s 10-Year ROE (%) Range
Min: -224.96   Max: -29.56
Current: -72.01

-224.96
-29.56
ROA (%) -58.38
DCTH's ROA (%) is ranked lower than
51% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. DCTH: -58.38 )
DCTH' s 10-Year ROA (%) Range
Min: -157.86   Max: -27.27
Current: -58.38

-157.86
-27.27
ROC (Joel Greenblatt) (%) -789.79
DCTH's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. DCTH: -789.79 )
DCTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -194983.33   Max: -161.78
Current: -789.79

-194983.33
-161.78
EBITDA Growth (3Y)(%) -38.40
DCTH's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. DCTH: -38.40 )
DCTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -38.4   Max: 56.5
Current: -38.4

-38.4
56.5
EPS Growth (3Y)(%) -36.90
DCTH's EPS Growth (3Y)(%) is ranked higher than
55% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. DCTH: -36.90 )
DCTH' s 10-Year EPS Growth (3Y)(%) Range
Min: -36.9   Max: 93.9
Current: -36.9

-36.9
93.9
» DCTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DCTH Guru Trades in Q4 2013

Jim Simons 2,875,138 sh (+1236.42%)
» More
Q1 2014

DCTH Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

DCTH Guru Trades in Q2 2014

Jim Simons 59,298 sh (New)
» More
Q3 2014

DCTH Guru Trades in Q3 2014

Jim Simons 161,798 sh (+172.86%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.63
DCTH's P/B is ranked higher than
97% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. DCTH: 0.63 )
DCTH' s 10-Year P/B Range
Min: 0.51   Max: 6.18
Current: 0.63

0.51
6.18
P/S 11.50
DCTH's P/S is ranked higher than
59% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. DCTH: 11.50 )
DCTH' s 10-Year P/S Range
Min: 9.33   Max: 1077.33
Current: 11.5

9.33
1077.33
EV-to-EBIT 0.46
DCTH's EV-to-EBIT is ranked higher than
100% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. DCTH: 0.46 )
DCTH' s 10-Year EV-to-EBIT Range
Min: -2.5   Max: 0.6
Current: 0.46

-2.5
0.6
Current Ratio 4.86
DCTH's Current Ratio is ranked higher than
85% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. DCTH: 4.86 )
DCTH' s 10-Year Current Ratio Range
Min: 0.58   Max: 67.13
Current: 4.86

0.58
67.13
Quick Ratio 4.76
DCTH's Quick Ratio is ranked higher than
87% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. DCTH: 4.76 )
DCTH' s 10-Year Quick Ratio Range
Min: 0.58   Max: 67.13
Current: 4.76

0.58
67.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.76
DCTH's Price/Net Cash is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DCTH: 0.76 )
DCTH' s 10-Year Price/Net Cash Range
Min: 1.1   Max: 62.95
Current: 0.76

1.1
62.95
Price/Net Current Asset Value 0.75
DCTH's Price/Net Current Asset Value is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DCTH: 0.75 )
DCTH' s 10-Year Price/Net Current Asset Value Range
Min: 1.08   Max: 54.55
Current: 0.75

1.08
54.55
Price/Tangible Book 0.63
DCTH's Price/Tangible Book is ranked higher than
97% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. DCTH: 0.63 )
DCTH' s 10-Year Price/Tangible Book Range
Min: 0.91   Max: 44.06
Current: 0.63

0.91
44.06
Price/Median PS Value 0.23
DCTH's Price/Median PS Value is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. DCTH: 0.23 )
DCTH' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 17.84
Current: 0.23

0.34
17.84
Earnings Yield (Greenblatt) 217.40
DCTH's Earnings Yield (Greenblatt) is ranked higher than
100% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. DCTH: 217.40 )
DCTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 169.1   Max: 8625
Current: 217.4

169.1
8625

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DV3.Germany,
Delcath Systems, Inc., is a Delaware corporation incorporated in August 1988. The Company is a pharmaceutical and medical device company focused on oncology. The Company has directed its research efforts towards the development and clinical study of the Delcath chemosaturation system. The Company's proprietary drug/device combination product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company operates in one business segment, which is the development and commercialization of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers high doses of chemotherapeutic agents directly to the liver, while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through standard interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs and the potential for concomitant cancer therapies. The Company assembles, sterilizes and packages the Delcath chemosaturation system at its facility in Queensbury, New York and has established its European headquarters and distribution facility in Galway, Ireland. It utilizes contract manufacturers to manufacture some components of the Delcath chemosaturation system. The Delcath chemosaturation system competes with all forms of liver cancer treatments. The Delcath chemosaturation system is subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
comment on DCTH Mar 15 2013 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
cooldecency99 note on DCTH May 01 2010 
cooldecency99 note on DCTH May 01 2010 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
Most active Nasdaq-traded stocks Dec 19 2014
DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 15 2014
DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS Dec 15 2014
DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS Dec 15 2014
DELCATH ADDS NEW CENTERS TO GLOBAL PHASE 2 HCC PROGRAM Dec 11 2014
DELCATH ADDS NEW CENTERS TO GLOBAL PHASE 2 HCC PROGRAM Dec 11 2014
DELCATH SYSTEMS, INC. Financials Nov 19 2014
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 18 2014
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 10 2014
DELCATH ANNOUNCES TREATMENT OF FIRST PATIENT IN PHASE 2 TRIAL OF MELPHALAN HEPATIC DELIVERY SYSTEM... Nov 10 2014
10-Q for Delcath Systems, Inc. Nov 07 2014
DELCATH SYSTEMS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report Nov 05 2014
Delcath Systems Inc Earnings Call scheduled for 4:30 pm ET today Nov 05 2014
Delcath Reports 2014 Third Quarter Results Nov 05 2014
Q3 2014 Delcath Systems, Inc. Earnings Release - After Market Close Nov 05 2014
DELCATH TO REPORT THIRD QUARTER 2014 RESULTS ON NOVEMBER 5, 2014 Oct 29 2014
DELCATH TO REPORT THIRD QUARTER 2014 RESULTS ON NOVEMBER 5, 2014 Oct 29 2014
LEADING CANCER CENTERS TO PRESENT DATA FROM DELCATH'S CHEMOSAT/MELPHALAN HDS AT ESSO CONGRESS Oct 28 2014
LEADING CANCER CENTERS TO PRESENT DATA FROM DELCATH'S CHEMOSAT/MELPHALAN HDS AT ESSO CONGRESS Oct 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK